Navigation Links
Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
Date:4/3/2009

EAST BRUNSWICK, N.J., April 3 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has entered into definitive agreements with select existing and new institutional investors to sell 5.93 million units consisting of (i) one share of its common stock, $0.01 par value per share, and (ii) one warrant to purchase 0.85 shares of its common stock in a registered direct offering for gross proceeds of approximately $31.0 million, before deducting placement agent's fees and estimated offering expenses. The investors have agreed to purchase the units for a negotiated price of $5.23 per unit.

The initial per share exercise price of the warrants is $10.46. In the event that the company publicly announces that the U.S. Food and Drug Administration has issued a "complete response letter" with respect to the company's Biologics License Application for its KRYSTEXXA(TM) (pegloticase) product candidate (the "BLA"), then the exercise price shall, from and after the eleventh trading day following the first such public announcement by the company, be changed to be the weighted average price for the common stock for the five trading days immediately preceding the tenth trading day following the date that the company publicly announced that the FDA issued its complete response letter. In no event may the exercise price exceed $10.46 or be less than $1.57.

The warrants are exercisable at any time on or after the date of issuance and expire on a date that varies based on the FDA's response to the BLA. If the FDA responds to the BLA with a "complete response letter" constituting approval or rejection of the BLA, then the warrants expire nine months after the date the company publicly announces that the FDA issued its complete response letter. If the FDA responds to the BLA with a "complete response
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
2. Savient Announces Appointment of David Gionco as Chief Financial Officer
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Submits Biologics License Application (BLA) for pegloticase
6. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
7. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
10. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences ... Decipher Prostate Cancer Classifier, a genomic test for prostate ... node-negative, high-risk men managed by radical prostatectomy without adjuvant ... prostatectomy is relatively uncommon, using tumor genomics to identify ... metastatic disease is an important advance. The study has ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Mylan Inc. (Nasdaq: MYL ) today announced ... it holds a 71.2% controlling interest, has been selected ... projects as the primary supplier of five antiretroviral (ARV) ... has been selected as the primary supplier of seven ...
... DIEGO, April 20 Trius Therapeutics, Inc. today announced ... H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, ... group of anti-infective thought leaders. Dr. Batts is ... and the Chief of Infectious Diseases at its ...
... -- Data presented at 100th Annual Meeting of the ... 19 Researchers from Dendreon Corporation (Nasdaq: ... Treatment and Early Cancer Treatment) or P-11 Phase 3 ... responses that are durable and can be maintained following ...
Cached Biology Technology:Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 2Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 3Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 4Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 5
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... student at Rensselaer Polytechnic Institute has learned very quickly ... medicine go down. In fact, with his invention, the ... most important and complex molecules in the human body, ... communicate with one another. Graduating senior Jeffery Martin has ...
... Mireya Correa, staff scientist at the Smithsonian Tropical Research ... Panama, received the Jos Cuatrecasas Medal for Excellence in ... the National Museum of Natural History and the United ... Botanical Symposium held at the museum. , Jos ...
... gas used as an agricultural pesticide, was introduced in ... and increase fruit yields. Agricultural production nurseries around the ... plants for export and domestic sales. In 2000, the ... and in 2005 MB was banned in the United ...
Cached Biology News:Undergrad has sweet success with invention of artificial Golgi 2Undergrad has sweet success with invention of artificial Golgi 3Smithsonian scientist receives 2008 Medal for Excellence in tropical botany 2Alternatives to ozone-depleting pesticide studied 2
... ,Kit containing Dermal Fibroblasts (Mouse/BalbC) and ... a long-term culture, and is guaranteed to ... growth from the date supplied, when used ... mouse/BalbC, embryonic day 18.5 ,Applications: ...
... QRT-PCR Mixes are formulated for use in ... SYBR Green. One-step QRT-PCR mixes offer a ... The pipetting steps are minimised, making the ... ,The 2x ABsolute QRT-PCR Mix is supplied ...
... are designed for protein pull-down ... sphingosine binding proteins. An order ... of agarose beads with 10 ... the terminus of the alkyl ...
... Immunogen: Synthetic Peptide: M(1) E ... P G P P T M D L ... from mouse cells.,PA1-072 has been successfully used in ... antibody detects an ~86 kDa protein representing Mint3 ...
Biology Products: